BRIEF-SCYNEXIS Resumes Patient Dosing In Phase 3 MARIO Study

Reuters
28 May
BRIEF-SCYNEXIS Resumes Patient Dosing In Phase 3 MARIO Study

May 28 (Reuters) - SCYNEXIS Inc SCYX.O:

  • SCYNEXIS RESUMES PATIENT DOSING IN PHASE 3 MARIO STUDY

  • SCYNEXIS INC - RESUMPTION OF DOSING TRIGGERS $10M MILESTONE PAYMENT FROM GSK

  • SCYNEXIS INC - WORKING TO RESOLVE DISAGREEMENT WITH GSK

  • SCYNEXIS INC - GSK DISPUTES MILESTONE PAYMENTS, SCYNEXIS DISAGREES WITH GSK'S POSITION

Source text: ID:nGNX9BwNBS

Further company coverage: SCYX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10